<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: market price", fill: "#ffb347"},
{source: "2: market price", target: "2: stock could decline", fill: "#ffb347"},
{source: "2: stock could decline", target: "2: uncertainties", fill: "#ffb347"},
{source: "2: uncertainties", target: "2: into actual events", fill: "#ffb347"},
{source: "2: market price", target: "5: licensing tagatose", fill: "#f88379"},
{source: "5: licensing tagatose", target: "5: beverage use", fill: "#f88379"},
{source: "5: beverage use", target: "5: biotechnology product", fill: "#f88379"},
{source: "5: biotechnology product", target: "5: royalties from", fill: "#f88379"},
{source: "5: royalties from", target: "5: tagatose by", fill: "#f88379"},
{source: "5: licensing tagatose", target: "6: continuing losses", fill: "#e2062c"},
{source: "6: continuing losses", target: "6: biotechnology", fill: "#e2062c"},
{source: "6: biotechnology", target: "6: adversely", fill: "#e2062c"},
{source: "6: adversely", target: "6: overall financial", fill: "#e2062c"},
{source: "6: continuing losses", target: "7: unsuccessful", fill: "#ffd700"},
{source: "7: unsuccessful", target: "7: commercializing", fill: "#ffd700"},
{source: "7: commercializing", target: "7: biotechnology products", fill: "#ffd700"},
{source: "7: biotechnology products", target: "7: will continue", fill: "#ffd700"},
{source: "7: will continue", target: "7: adversely affected", fill: "#ffd700"},
{source: "7: unsuccessful", target: "10: competitor", fill: "#002e63"},
{source: "10: competitor", target: "16: operations", fill: "#ff4040"},
{source: "16: operations", target: "16: adverse impact on", fill: "#ff4040"},
{source: "16: operations", target: "17: revenues from contracts with", fill: "#b87333"},
{source: "17: revenues from contracts with", target: "17: federal government", fill: "#b87333"},
{source: "17: federal government", target: "17: development", fill: "#b87333"},
{source: "17: development", target: "17: will continue", fill: "#b87333"},
{source: "17: will continue", target: "17: depend on", fill: "#b87333"},
{source: "17: depend on", target: "17: successful participation", fill: "#b87333"},
{source: "17: successful participation", target: "17: federal government contract programs", fill: "#b87333"},
{source: "17: revenues from contracts with", target: "19: federal government", fill: "#b38b6d"},
{source: "19: federal government", target: "19: government", fill: "#b38b6d"},
{source: "19: government", target: "19: budgetary constraints affecting", fill: "#b38b6d"},
{source: "19: budgetary constraints affecting", target: "19: spending generally", fill: "#b38b6d"},
{source: "19: spending generally", target: "19: specific departments", fill: "#b38b6d"},
{source: "19: specific departments", target: "19: fiscal policies", fill: "#b38b6d"},
{source: "19: fiscal policies", target: "19: available funding", fill: "#b38b6d"},
{source: "19: available funding", target: "19: technological developments", fill: "#b38b6d"},
{source: "19: technological developments", target: "19: federal governmental shutdowns", fill: "#b38b6d"},
{source: "19: federal governmental shutdowns", target: "19: government appropriations process", fill: "#b38b6d"},
{source: "19: government appropriations process", target: "19: invoices by government", fill: "#b38b6d"},
{source: "19: invoices by government", target: "19: payment offices due", fill: "#b38b6d"},
{source: "19: payment offices due", target: "19: problems with", fill: "#b38b6d"},
{source: "19: problems with", target: "19: competition", fill: "#b38b6d"},
{source: "19: competition", target: "19: consolidation", fill: "#b38b6d"},
{source: "19: consolidation", target: "19: general economic conditions", fill: "#b38b6d"},
{source: "19: federal government", target: "22: developments", fill: "#0247fe"},
{source: "22: developments", target: "22: technology", fill: "#0247fe"},
{source: "22: developments", target: "23: competitors", fill: "#fefe22"},
{source: "23: competitors", target: "23: applications", fill: "#fefe22"},
{source: "23: competitors", target: "53: December ", fill: "#000080"},
{source: "53: December ", target: "53: December ", fill: "#000080"},
{source: "53: December ", target: "53: million respectively", fill: "#000080"},
{source: "53: December ", target: "57: operations through private placements", fill: "#c00"},
{source: "57: operations through private placements", target: "57: common stock", fill: "#c00"},
{source: "57: common stock", target: "57: warrants issued", fill: "#c00"},
{source: "57: warrants issued", target: "57: connection with", fill: "#c00"},
{source: "57: connection with", target: "57: such private placement transactions", fill: "#c00"},
{source: "57: operations through private placements", target: "START_HERE", fill: "#c00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biotechnology">Biotechnology</a></td>
      <td>Biotechnology is "the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services". The term biotechnology was first used by Károly Ereky in 1919, meaning the production of products from raw materials with the aid of living organisms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biotechnology_in_India">Biotechnology in India</a></td>
      <td>Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India.\n\n\n== Department of Biotechnology ==\n\nThe Department of Biotechnology (DBT) is an Indian government department, under the Ministry of Science and Technology responsible for administering development and commercialization in the field of modern biology and biotechnology in India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Outline_of_biotechnology">Outline of biotechnology</a></td>
      <td>The following outline is provided as an overview of and topical guide to biotechnology:\nBiotechnology – field of applied biology that involves the use of living organisms and bioprocesses in engineering, technology, medicine and other fields requiring bioproducts. Biotechnology also utilizes these products for manufacturing purposes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/NASDAQ_Biotechnology_Index">NASDAQ Biotechnology Index</a></td>
      <td>The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. A list of the 213 components of the index is published online.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SPHERIX INC      Item 1A  RISK FACTORS         Any of the <font color="blue">risk factors</font> we describe below <font color="blue">could severely harm</font> our business,     <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our common     <font color="blue">stock <font color="blue">could decline</font></font> if one or more of these risks and <font color="blue">uncertainties</font> develop     <font color="blue">into actual events</font></td>
    </tr>
    <tr>
      <td>8     ______________________________________________________________________                                                                     RISKS RELATED TO OUR BUSINESS         WE CONTINUE TO BE DEPENDENT ON OUR INFORMATION SERVICES DIVISION FOR NEARLY     ALL OF OUR REVENUE  We are <font color="blue">almost entirely dependent on</font> the information     services  division  for  our  revenue</td>
    </tr>
    <tr>
      <td>Despite <font color="blue">licensing tagatose</font> in 1996 for food and <font color="blue">beverage use</font>, our principal     <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>, we have yet to receive any substantial <font color="blue">royalties from</font>     the sales of <font color="blue">tagatose by</font> our licensee</td>
    </tr>
    <tr>
      <td>Thus, we have incurred substantial     and <font color="blue">continuing losses</font> in our <font color="blue">bio<font color="blue">technology</font></font> division which have <font color="blue">adversely</font>     affected our <font color="blue">overall financial</font> results and our stock price</td>
    </tr>
    <tr>
      <td>If we continue     to  be <font color="blue">unsuccessful</font> in <font color="blue">commercializing</font> our <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>s, our     financial results <font color="blue">will continue</font> to be <font color="blue">adversely</font> affected to the detriment of     our stock price</td>
    </tr>
    <tr>
      <td>OUR LARGEST INFORMATION SERVICES CONTRACT COULD BE AWARDED TO A COMPETITOR     In both 2005 and 2004, our NPRS <font color="blue">contract accounted</font> for approximately 17prca of     our <font color="blue">aggregate revenue</font></td>
    </tr>
    <tr>
      <td>This contract has <font color="blue">been bundled with</font> a National     Forest Services contract and rebid as the National Recreation Reservation     System  (“NRRS”)</td>
    </tr>
    <tr>
      <td>In 2005, the bundled NRRS contract was awarded to a     <font color="blue">competitor</font> for the second time; we protested and our protest was again     upheld</td>
    </tr>
    <tr>
      <td>This  is  the second time that GAO has found the USDA Forest     Service’s  attempt  to award the NRRS contract to our <font color="blue">competitor</font> to be     flawed</td>
    </tr>
    <tr>
      <td><font color="blue">The Department of Agriculture </font>has <font color="blue">subsequently decided</font> not to     follow GAO’s decision and is seeking to <font color="blue">proceed with</font> the award of the NRRS     contract to our <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>Spherix has filed an appeal of this <font color="blue">action with</font>     the  Court of Federal Claims, but we <font color="blue">cannot predict</font> the outcome of the     appeal</td>
    </tr>
    <tr>
      <td><font color="blue">The Department of Agriculture </font>has agreed not to <font color="blue">proceed while</font> the     <font color="blue">Court of Federal Claims </font>hears Spherix’s appeal</td>
    </tr>
    <tr>
      <td>Meanwhile, the Company’s     NPRS contract has <font color="blue">been formally extended through</font> <font color="blue">September </font>30, 2006</td>
    </tr>
    <tr>
      <td>If we     lose this contract, we will need to replace it with other work or scale back     our <font color="blue">operations</font> to avoid an <font color="blue">adverse impact on</font> our financial results</td>
    </tr>
    <tr>
      <td>OUR INFORMATION SERVICES BUSINESS COULD BE ADVERSELY AFFECTED BY SIGNIFICANT     CHANGES  IN  THE  CONTRACTING  OR  FISCAL POLICIES OF THE US FEDERAL     GOVERNMENT  We derive substantial <font color="blue">revenues from contracts with</font> the US     <font color="blue">federal <font color="blue">government</font></font> and we believe that the success and <font color="blue">development</font> of our     business <font color="blue">will continue</font> to <font color="blue">depend on</font> our <font color="blue">successful participation</font> in US     <font color="blue">federal <font color="blue">government</font></font> contract programs</td>
    </tr>
    <tr>
      <td>Accordingly, changes in US federal     <font color="blue">government</font>  <font color="blue">contracting</font>  policies  <font color="blue">could directly affect</font> our financial     performance</td>
    </tr>
    <tr>
      <td>Among the factors that could have a material adverse affect on     our US <font color="blue">federal <font color="blue">government</font></font> <font color="blue">contracting</font> business are:         •                  <font color="blue">budgetary constraints affecting</font> US <font color="blue">federal <font color="blue">government</font></font>     <font color="blue">spending generally</font>, or <font color="blue">specific departments</font> or agencies in particular, and     changes in <font color="blue">fiscal policies</font> or <font color="blue">available funding</font>;       •                  technological <font color="blue">development</font>s;       •                  US <font color="blue">federal <font color="blue">government</font></font>al shutdowns and other potential     delays in the <font color="blue">government</font> appropriations process;       •                  delays in the payment of our invoices by <font color="blue">government</font>     <font color="blue">payment offices due</font> to <font color="blue">problems with</font>, or upgrades to, <font color="blue">government</font> information     systems, or for other reasons;       •                  <font color="blue">competition</font> and <font color="blue">consolidation</font> in the information services     industry; and       •                  <font color="blue">general economic conditions</font></td>
    </tr>
    <tr>
      <td>OUR INFORMATION SERVICES BUSINESS IS RELIANT ON TECHNOLOGY  We have devoted     <font color="blue"><font color="blue">significant</font> resources</font> to developing and acquiring <font color="blue">specialized hardware</font> and     software  in  our  information  services business</td>
    </tr>
    <tr>
      <td>In order to remain     <font color="blue">competitive</font>, we <font color="blue">must continue</font> to select, invest in, acquire and develop new     and <font color="blue">enhanced <font color="blue">technology</font> on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>We may not be successful in     these efforts or in anticipating <font color="blue">development</font>s in <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">competitor</font>s  could  develop similar <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties could</font>     <font color="blue">independently</font> develop similar <font color="blue">technology</font>, obtain <font color="blue">unauthorized access</font> to our     <font color="blue">proprietary</font> <font color="blue">technology</font> or misappropriate <font color="blue">technology</font> to which we have granted     access</td>
    </tr>
    <tr>
      <td>Failure to remain current with <font color="blue">technology</font> or <font color="blue">misappropriation</font> of     our <font color="blue">technology</font> could <font color="blue">adversely</font> affect our ability to compete for information     services business and could lead to reduced business and reduced financial     results</td>
    </tr>
    <tr>
      <td>ROYALTIES FROM TAGATOSE SALES ARE UNCERTAIN  We have developed tagatose, a     full  bulk,  low  <font color="blue">calorie sweetener</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">September </font>1996, we granted an     exclusive, world-wide license to a foreign entity for the <font color="blue">manufacture</font> and     sale of tagatose for use in foods and beverages</td>
    </tr>
    <tr>
      <td>To date, tagatose has only     <font color="blue">been commercially introduced into</font> a limited number of products</td>
    </tr>
    <tr>
      <td>We initiated an <font color="blue">arbitration</font>     <font color="blue">proceeding against</font> our <font color="blue">licensee due</font> to the delay in <font color="blue">bringing tagatose</font> to     market</td>
    </tr>
    <tr>
      <td>We <font color="blue">subsequently dismissed</font> the <font color="blue">arbitration</font> in exchange for various     <font color="blue">agreements</font> including an extension of the <font color="blue">period during which</font> we are entitled     to                                           9     ______________________________________________________________________         receive royalties</td>
    </tr>
    <tr>
      <td>Our prospects for receiving <font color="blue">royalties from</font> tagatose food     and <font color="blue">beverage sales</font> are <font color="blue">uncertain due</font> to numerous factors, most of which are     out of our control, including:         •                    our  licensee  has  exclusive  control  over  the     <font color="blue">commercialization</font> of tagatose for food and <font color="blue">beverage use</font>s;       •                  the delay in <font color="blue">bringing tagatose</font> to market results in a     shortening of the time we are entitled to royalties;       •                  <font color="blue"><font color="blue">significant</font> royalties</font> are <font color="blue">possible only</font> if our licensee     <font color="blue">constructs</font>  a  larger tagatose manufacturing facility; at present, our     licensee  has  <font color="blue">ceased production at</font> its <font color="blue">current facility due</font> to excess     <font color="blue">inventories</font>; and       •                  we are entitled to <font color="blue">royalties only</font> after <font color="blue">reimbursing</font> our     licensee for the <font color="blue">ongoing costs</font> of maintaining <font color="blue">patent protection on tagatose</font>     <font color="blue">throughout</font> the world</td>
    </tr>
    <tr>
      <td>WE  HAVE NOT YET SUCCESSFULLY COMMERCIALIZED NATURLOSE  We are in the     process of attempting to develop other uses of tagatose, under the brand     name Naturlose, in non-food products such as toothpaste, mouthwash, and     over-the-counter and <font color="blue">pharmaceutical</font> drugs</td>
    </tr>
    <tr>
      <td>To date, we have yet to secure     any substantial <font color="blue">revenue from</font> Naturlose sales</td>
    </tr>
    <tr>
      <td>One of the hurdles we will     have to overcome is that our <font color="blue">foreign licensee</font> for tagatose (which has the     exclusive right to <font color="blue">manufacture</font> tagatose) does not currently have sufficient     <font color="blue">capacity</font> to <font color="blue">manufacture</font> enough tagatose to <font color="blue">supply both food</font> and nonfood     markets  if  such  markets  mature  and grow</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">successfully</font>     <font color="blue">commercialize</font> Naturlose may <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td>OTHER  BIOTECH  PRODUCTS  ARE  STILL IN THE DEVELOPMENT STAGE  We are     developing other <font color="blue">biotech products</font></td>
    </tr>
    <tr>
      <td>None of these have been developed to a     stage where any <font color="blue"><font color="blue">significant</font> revenue</font> has <font color="blue">been generated</font></td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>of     products will require <font color="blue">significant</font> <font color="blue">additional</font> research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">additional</font>  effort  will  require substantial <font color="blue">funding which may</font> not be     available to us</td>
    </tr>
    <tr>
      <td>Further, our research and <font color="blue">development</font> activities may not     result in any <font color="blue">saleable products</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that we <font color="blue">will license</font>     or seek an <font color="blue">affiliation with</font> a <font color="blue">third party</font> to bring some products to market</td>
    </tr>
    <tr>
      <td>In such an event, we <font color="blue">would likely</font> have <font color="blue">minimal control over</font> the <font color="blue">manufacture</font>     and marketing of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>DEVELOPMENT OF ANY BIOTECH PRODUCTS WILL DEPEND ON OBTAINING FDA AND FOREIGN     REGULATORY APPROVALS  <font color="blue">Development </font>of new products are subject to extensive     regulation by <font color="blue">government</font>al <font color="blue">regulatory</font> <font color="blue">authorities</font> <font color="blue">in the United States </font>and     other countries</td>
    </tr>
    <tr>
      <td>These rigorous <font color="blue">regulatory</font> approval processes can take five     to ten years or more and require the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>We may not be able to obtain the <font color="blue">necessary approvals</font> for <font color="blue">clinical testing</font> or     for  the  marketing  of products</td>
    </tr>
    <tr>
      <td><font color="blue">Continuing </font>failure to <font color="blue">commercialize</font>     <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>s may <font color="blue">adversely</font> affect our financial results and stock     price</td>
    </tr>
    <tr>
      <td>OUR SUCCESS WILL DEPEND, IN PART, ON OUR ABILITY TO OBTAIN AND MAINTAIN     PATENT PROTECTION FOR OUR PRODUCTS  We have <font color="blue">several patents</font> for tagatose     and  other  products  under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain     <font color="blue">additional</font>  patents</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">future patents may</font> not be held valid if     <font color="blue">subsequently challenged</font></td>
    </tr>
    <tr>
      <td>Failure to obtain and maintain patent protection     for our <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>s may further delay or eliminate our ability to     <font color="blue">commercialize</font>  <font color="blue">such products</font>, which may <font color="blue">adversely</font> affect our financial     results and stock price</td>
    </tr>
    <tr>
      <td>WE  HAVE SUSTAINED LOSSES IN THE PAST AND WE MAY SUSTAIN LOSSES IN THE     FUTURE  We have <font color="blue">incurred losses</font> in <font color="blue">prior years</font>, including the last three     (3) years</td>
    </tr>
    <tr>
      <td>Our net losses for the years ended <font color="blue">December </font>31, 2005, <font color="blue">December </font>    31, 2004 and <font color="blue">December </font>31, 2003 were dlra2dtta8 million, dlra2dtta8 million and dlra2dtta3     million, respectively</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net accumulated losses from</font> the date of our     <font color="blue">organization through</font> <font color="blue">December </font>31, 2005 are dlra15dtta2 million</td>
    </tr>
    <tr>
      <td>We may not return     to profitable <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE MAY NOT BE ABLE TO OBTAIN ADDITIONAL FINANCING THAT WE WILL NEED  During     2005, our working capital decreased by dlra1dtta1 million, largely as a result of     the <font color="blue">incurred losses</font> and <font color="blue">continued <font color="blue">investment</font></font> in our business</td>
    </tr>
    <tr>
      <td>In recent     years, we have funded our <font color="blue">operations</font> through private placements of our     <font color="blue">common stock</font> and through the exercise of <font color="blue">warrants issued</font> in <font color="blue">connection with</font>     <font color="blue">such private placement <font color="blue"><font color="blue">transaction</font>s</font></font></td>
    </tr>
    <tr>
      <td>We believe that we may need to raise     <font color="blue">additional</font>  funding  to  continue  to  finance our product <font color="blue">development</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may also need to raise <font color="blue">additional</font> money to fund <font color="blue">operations</font>     if the sale of <font color="blue">tagatose as</font> a food and beverage product continues to be     delayed or is not <font color="blue">as successful as</font> we anticipate</td>
    </tr>
    <tr>
      <td>We may not be able to     obtain <font color="blue">additional</font> financing on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Failure to     obtain required financing may cause us to curtail or cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>None of our key employees have <font color="blue">employment</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Further, our Chief Science Officer, who is <font color="blue">principally</font> responsible for                                           10     ______________________________________________________________________         <font color="blue">commercializing</font> our <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>s, is 81 years of age</td>
    </tr>
    <tr>
      <td>The loss of     the services of one or more of <font color="blue">such employees could</font> have a material adverse     effect on us</td>
    </tr>
    <tr>
      <td>WE  FACE  INTENSE  COMPETITION  BY COMPETITORS IN BOTH DIVISIONS  Our     <font color="blue">competitor</font>s in the information services business are numerous</td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue">competitor</font>s have <font color="blue">significant</font>ly greater financial, marketing and <font color="blue">distribution</font>     resources  than we do</td>
    </tr>
    <tr>
      <td>Our principal information services <font color="blue">competitor</font>,     ReserveAmerica, is a division of <font color="blue">Ticketmaster </font>which is a subsidiary of     IAC/InterActive Corp, a <font color="blue">significant</font>ly larger public company than Spherix</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s may succeed in developing or <font color="blue">marketing technologies</font> and     <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> product</font>s that are more <font color="blue">effective than ours</font></td>
    </tr>
    <tr>
      <td><font color="blue">Alternative     </font>sweetener(s) may <font color="blue">adversely</font> affect sales of tagatose</td>
    </tr>
    <tr>
      <td>In the past year or     two, the alternate sweetener Splenda has made substantial <font color="blue">inroads into</font>     markets we expected tagatose to capture</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK         THE PRICE OF SPHERIX’S COMMON STOCK HAS BEEN HIGHLY VOLATILE DUE TO SEVERAL     FACTORS WHICH WILL CONTINUE TO EFFECT THE PRICE OF OUR STOCK  Our common     stock has traded as low as dlra1dtta19 and as high as dlra5dtta85 between January 3,     2005 and <font color="blue">December </font>30, 2005</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">factors leading</font> to this <font color="blue">volatility</font>     include:         •                  <font color="blue">relatively</font> small amounts of our <font color="blue">stock trading on</font> any     given day;       •                  <font color="blue">fluctuations</font> in our operating results;       •                   <font color="blue">announcements</font>  of <font color="blue">technological innovations</font> or new     <font color="blue">products which</font> we or our <font color="blue">competitor</font>s make;       •                  <font color="blue">development</font>s with respect to patents or <font color="blue">proprietary</font>     rights; and       •                  the status of our licensee’s efforts to <font color="blue">market tagatose</font></td>
    </tr>
    <tr>
      <td>CORNELL CAPITAL PARTNERS WILL PAY LESS THAN THE MARKET PRICE AND WILL HAVE     AN  INCENTIVE  TO  SELL ITS SHARES, WHICH MAY CAUSE OUR STOCK PRICE TO     DECLINE  <font color="blue">Cornell Capital Partners </font><font color="blue">will purchase shares</font> of our <font color="blue">common stock</font>     pursuant to the Standby Equity Distribution Agreement (SEDA) at a purchase     price that is less than the then-prevailing <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td><font color="blue">Cornell Capital Partners </font>will have an incentive to <font color="blue">immediately sell</font>     any shares of our <font color="blue">common stock</font> that it purchases pursuant to the SEDA to     realize  a  gain  on the difference between the purchase price and the     then-prevailing <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>To the extent Cornell     Capital  Partners  sells  its <font color="blue">common stock</font>, the <font color="blue">common stock</font> price may     decrease</td>
    </tr>
    <tr>
      <td>NEW SHAREHOLDERS WILL EXPERIENCE SIGNIFICANT DILUTION FROM OUR SALE OF     SHARES UNDER THE SEDA  The sale of <font color="blue">shares pursuant</font> to the SEDA will have a     <font color="blue">dilutive impact on</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As a result, our net income per share     could decrease in future periods, and the <font color="blue">market price</font> of our <font color="blue">common stock</font>     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>In addition, the lower our stock price, the more shares of     <font color="blue">common stock</font> we will have to issue under the SEDA  If our stock price is     lower, then our existing <font color="blue">stockholders</font> would experience <font color="blue">greater dilution</font></td>
    </tr>
    <tr>
      <td>OUR COMMON STOCK WILL BE DELISTED FROM NASDAQ NATIONAL MARKET SYSTEM IF WE     FAIL TO COMPLY WITH CONTINUED LISTING STANDARDS  We were <font color="blue">previously advised</font>     that we were in danger of our <font color="blue">common stock</font> being <font color="blue">delisted from</font> the <font color="blue">NASDAQ     </font>National  Market due to our <font color="blue">stockholders</font>’ equity falling below the dlra10     million  minimum  <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>At  <font color="blue">December </font> 31, 2005, the Company’s     shareholder’s equity was dlra7cmam879cmam220, or dlra2cmam120cmam780 below the dlra10cmam000cmam000     required by NASDAQ; however, <font color="blue">the Company </font>has subsequently raised, as of     March 10, 2006, an <font color="blue">additional</font> dlra2dtta7 million through the SEDA and warrant     <font color="blue"><font color="blue">transaction</font>s</font> so as to bring <font color="blue">the Company </font><font color="blue">into compliance with</font> the <font color="blue">NASDAQ     </font>equity <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>If at some point we are unable to meet the listing     standards,  we  intend to apply to list our <font color="blue">common stock</font> on the <font color="blue">NASDAQ     </font>SmallCap Market</td>
    </tr>
    <tr>
      <td>DIVIDENDS ON OUR COMMON STOCK ARE NOT LIKELY  We intend to retain future     earnings, if any, in order to <font color="blue">provide funds</font> for use in the operation and     expansion  of  our  business and for <font color="blue">further research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Accordingly, we do not anticipate <font color="blue">paying cash dividends on</font> our <font color="blue">common stock</font>     in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font><font color="blue">must look solely</font> to <font color="blue">appreciation</font> in     the <font color="blue">market price</font> of the shares of our <font color="blue">common stock</font> to obtain a return on     their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>BECAUSE  OF THE RIGHTS AGREEMENT AND “ANTI-TAKEOVER” PROVISIONS IN OUR     CERTIFICATE OF INCORPORATION AND BYLAWS, A THIRD PARTY MAY BE DISCOURAGED     FROM MAKING A TAKEOVER OFFER WHICH COULD BE BENEFICIAL TO OUR STOCKHOLDERS     In 2001, we adopted a <font color="blue">shareholder rights</font> plan</td>
    </tr>
    <tr>
      <td>The effect of this rights     plan and of <font color="blue">certain provisions</font> of our Certificate of Incorporation, By-Laws,     and the anti-takeover provisions of the Delaware General Corporation Law,     <font color="blue">could delay</font> or                                           11     ______________________________________________________________________         prevent a <font color="blue">third party</font> from acquiring us or <font color="blue">replacing members</font> of our board of     <font color="blue">directors</font>, even if the <font color="blue">acquisition</font> or the <font color="blue">replacements would</font> be <font color="blue">beneficial</font>     to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could also reduce</font> the price that certain     <font color="blue">investors might</font> be willing to pay for shares of the <font color="blue">common stock</font> and result     in the <font color="blue">market price</font> being lower than it would be without these provisions</td>
    </tr>
    <tr>
      <td>INSIDERS OWN A SIGNIFICANT PORTION OF OUR COMMON STOCK, WHICH COULD LIMIT     OUR STOCKHOLDERS’ ABILITY TO INFLUENCE THE OUTCOME OF KEY TRANSACTIONS  As     of <font color="blue">December </font>31, 2005, our officers and <font color="blue">directors</font> and their <font color="blue">affiliates</font> owned     approximately 20prca of the <font color="blue">outstanding shares</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a     result, our officers and <font color="blue">directors</font> are able to exert considerable influence     over the outcome of any <font color="blue">matters submitted</font> to a vote of the holders of our     <font color="blue">common stock</font>, including the election of our Board of Directors</td>
    </tr>
    <tr>
      <td>The voting     power of these <font color="blue">stockholders</font> could prevent or <font color="blue">frustrate attempts</font> to effect a     <font color="blue">transaction</font> that is in the <font color="blue">best interests</font> of the other <font color="blue">stockholders</font> and     <font color="blue">could also discourage others from seeking</font> to purchase our <font color="blue">common stock</font>,     <font color="blue">which might depress</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>WE  EXPERIENCE QUARTERLY VARIATIONS IN OUR OPERATING RESULTS  We have     experienced and expect to continue to experience <font color="blue">quarterly variations</font> in     revenues and operating income as a result of many factors, including the     <font color="blue">seasonality</font> of our information services business, timing of customers’     budget  processes and slowdowns or <font color="blue">accelerations</font> of work <font color="blue">by customers</font></td>
    </tr>
    <tr>
      <td>General work <font color="blue">economic conditions may</font> result in <font color="blue">customer deferral</font> of projects     or <font color="blue">cancellation</font> in planned <font color="blue">expenditure</font>s</td>
    </tr>
    <tr>
      <td>These factors may <font color="blue">adversely</font> affect     our financial results and our stock price</td>
    </tr>
  </tbody>
</table>